SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy.
Zheng X, Lin J, Xiong J, Guan Y, Lan B, Li Y, Gao X, Fei Z, Chen L, Chen L, Chen L, Chen G, Guo Z, Yi X, Cao W, Ai X, Zhou C, Li X, Zhao J, Yan X, Yu Q, Si L, Chen Y, Chen C.
Zheng X, et al. Among authors: li y, li x.
BMC Cancer. 2023 Jul 21;23(1):686. doi: 10.1186/s12885-023-10920-4.
BMC Cancer. 2023.
PMID: 37479966
Free PMC article.